A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium

Sponsor
Amgen
Study ID
NCT03096990
Status
Completed

Conditions

  • Arthritis, Psoriatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • apremilast — DRUG
    Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium

Study Details

The study will include a representative sample of 150 patients with active Psoriatic Arthritis (PsA) for whom the treating rheumatologist has decided to begin treatment with apremilast. This study is non-interventional, drug dosing and treatment duration will be at the sole discretion of the treating rheumatologist, in accordance with the local label and daily clinical practice. APOLO is a national (Belgium), multicentre, prospective, non-interventional, post-marketing study.

Key Dates

First listed
Mar 31, 2017
Start date
Apr 21, 2017
Status verified
Apr 2020
Primary completion
Dec 27, 2018
Completion
Dec 27, 2018

Study Design

Enrollment
106 participants (actual)

Arms

  • Arm: Use of apremilast in patients with active PsA
    Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium

Primary Outcome Measure

Proportion of patients showing response assessed by improvement for at least 2 out of 4 measures which compose the Psoriatic Arthritis Response Criteria (PsARC) at 6 months after apremilast initiation with respect to baseline [ Time Frame: 6 months after Apremilast initiation ]

Related Studies